The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

Long Covid–the disease encompassing the post-acute sequelae of SARS-CoV-2 (PASC)—
affects millions of people around the world. Prevention of PASC is an urgent public health …

Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization
or death within 30 days as compared with untreated controls previously uninfected and …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and
treatment on the development and persistence of Long COVID have intensified. Methods …

We conducted a retrospective cohort study to assess whether treatment with
nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …